Menu

Pharma News

picture04

Actavis plans entry to biosimilars market with Bioton agreement

Home/Pharma News | Posted 24/09/2010

In a press release on 7 September 2010, Icelandic generics’ manufacturer Actavis announced that it plans to enter into the field of biosimilars with an agreement with Polish biotechnology company, Bioton.

picture21

Ranbaxy to transfer R & D and focus on generics

Home/Pharma News | Posted 13/08/2010

On 2 July 2010, the Japanese Daiichi Sankyo Group and Indian-based Ranbaxy Laboratories announced that Ranbaxy’s New Drug Discovery Research (NDDR) has been transferred to Daiichi Sankyo India Pharma as part of the strategy to strengthen the global Research and Development (R & D) structure of the Daiichi Sankyo Group.

picture16

Ranbaxy to pay FDA to end impasse on manufacturing ban

Home/Pharma News | Posted 17/09/2010

Daiichi Sankyo hopes that its interventions may lead to a lift of the FDA’s import ban on 30 products from Ranbaxy, its Indian generic drugs arm.

picture02

Sun Pharma blocks Wockhardt settlement

Home/Pharma News | Posted 17/09/2010

Troubled generics’ firm Wockhardt is set to raise US$100 million via its foreign currency convertible bonds (FCCBs). However, fellow Indian generics’ manufacturer, Sun Pharma, has objected to the deal, amongst much speculation as to what Sun Pharma’s intentions are.

picture35

Teva increases its global position with acquisition of Ratiopharm

Home/Pharma News | Posted 10/09/2010

Generics are becoming an increasingly lucrative market with good prospects for the future. However, a report by US market data provider BCC Research shows that this is also a bit of an exclusive club. The top four global generics manufacturers in 2009 – Teva, Sandoz, Mylan and Watson – accounted for 40% of the world market.

The global generic medicines market

Home/Pharma News | Posted 03/09/2010

The global market for generic drugs was worth an estimated US$84 billion for 2009 and is expected to increase to a staggering US$168.7 billion by 2014.

picture24

Generics’ manufacturer Hospira merges with Javelin

Home/Pharma News | Posted 10/08/2010

On 22 June 2010, Hospira announced that it had successfully acquired 79% of the stock in Javelin Pharmaceutical’s. The merger agreement also allows for Hospira to exercise a ‘top-up’ option to increase its share ownership in Javelin, which, states Hospira, it fully intends to do.

picture03

Sanofi-aventis and Nichi-Iko announce joint venture for generics in Japan

Home/Pharma News | Posted 02/07/2010

Sanofi-aventis and Nichi-Iko Pharmaceutical Co., Ltd. (Nichi-Iko) have announced that they have signed an agreement to establish a new joint venture, called sanofi-aventis Nichi-Iko KK, in order to develop a generic business in Japan.

picture12

Orchid acquires US generic sales and marketing company Karalex

Home/Pharma News | Posted 25/06/2010

On 10 June 2010, Indian-based generics manufacturer, Orchid Chemicals & Pharmaceuticals (Orchid) announced that it had entered into an agreement to acquire Karalex Pharma, LLC, a US-based generic marketing and sales services company with headquarters in New Jersey, USA.

picture09

GSK acquires Argentine generics’ maker Laboratorios Phoenix

Home/Pharma News | Posted 25/06/2010

On 10 June 2010 GlaxoSmithKline (GSK) acquired Laboratorios Phoenix, a leading Argentine pharmaceutical business, for approximately US$253 million. GSK will gain full ownership of Phoenix in a move to accelerate sales growth and further extend its pharmaceutical portfolio in Argentina and the Latin America region.

picture06

Abbott acquires Indian generics’ maker Piramal Healthcare

Home/Pharma News | Posted 18/06/2010

The US-based company, Abbott, agreed to buy the domestic unit of Piramal Healthcare, one of India’s biggest generics makers, for US$3.7 billion.

picture28

EGA welcomes MEPs decisions on falsified medicines and pharmacovigilance reports

Home/Pharma News | Posted 11/06/2010

On 27 April 2010, ENVI (The Committee on the Environment, Public Health and Food Safety) of the European Parliament voted to adopt reports on both falsified medicines and pharmacovigilance. The measures included in these reports are intended to increase patients’ safety. This can only be good news for the generics sector, as this should result in increased consumer confidence and as a result encourage acceptance and increase sales of generics.

picture15

IMS Health Top 20 pharmaceutical companies 2009

Home/Pharma News | Posted 23/04/2010

The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.

picture18

IMS Health, BCC: Generics sales continue to climb

Home/Pharma News | Posted 12/03/2010

Over the 12 months that ended September 2009, global sales of generics grew by 7.7%, up from 3.6 % the year before, IMS Health reported. This compares with the 5.7% growth seen within the overall global pharmaceutical universe in 2009.

picture23

Global generics: time for consolidation and expansion

Home/Pharma News | Posted 12/03/2010

The global generic drug industry has witnessed an almost decade-long sales euphoria. Volumes and sales growth of prescription generic drugs continued to increase in 2009. At the same time, large companies are consolidating their operations in established markets and/or expanding into emerging ones through local acquisitions or partnerships.

picture12

After generics slow down in 2013: into biosimilars

Home/Pharma News | Posted 12/03/2010

Large pharmaceutical companies are consolidating their generics operations in established markets and/or expanding into emerging ones through local acquisitions or partnerships, writes Ms Doris de Guzman on ICIS website of 10 February 2010.

picture06

Originator/generic competition: who's the 'bad guy'?

Home/Pharma News | Posted 26/02/2010

As reported in Scrip News on 28 January 2010 by Xavier Buffet Delmas and Laura Morelli of Hogan & Hartson MNP, Paris, intellectual property rights are key elements of the fierce competition between originator and generics companies. Patents are central because it is only when patents elapse that generic products can enter the market. This is when competition in the market begins. Trademarks, trade dress and other marketing tools then come into play. The authors explain some interesting recent legal developments linked to this battle.

picture10

Indian Ranbaxy buys Biovel to strengthen in vaccines and follow-on biologics

Home/Pharma News | Posted 12/02/2010

Ranbaxy Laboratories in India (now part of Daiichi Sankyo) has strengthened its vaccine and biologicals manufacturing capabilities by acquiring India-based Biovel Lifesciences.

picture09

Pharmalot: Are pay-for-delay deals good or bad?

Home/Pharma News | Posted 11/02/2010

On 13 January 2010, the Federal Trade Commissioner (FTC) Jon Leibowitz held a press conference to deride the ongoing practice in which brand-name drugmakers offer cash or some other inducement to their generic rivals, which, in turn, agree to delay the marketing of lower-cost copycat medicines.

picture12

PhRMA threatens to withdraw US healthcare reform support

Home/Pharma News | Posted 10/02/2010

As reported by PharmaTimes on 18 January 2010, US research-based drugmakers have threatened to withdraw their support for US President Barack Obama’s healthcare reforms unless biological drugs receive 12 years’ guaranteed protection from generic competition.